Date Founded




Type of Company


Employees (Worldwide)



Wholesale: Consumer Non-Durables/Sundries

Company Description

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Executives & Employees

Chief Executive Officer & Chairman of the Executive Committee

Executive Vice President Chief Financial Officer

Chief Operating Officer

Executive Vice President Chief Operating Officer

Executive Vice President General Counsel

Executive Vice President Chief Marketing Officer

Chief Scientific Officer & Executive Vice President

Executive Vice President New Medicines Head & Chief Scientific Officer

Chief Medical Officer & Head, Development & Medical Practices

Chief Talent Officer

Board of Directors

Vice Chairman at UCB Pharma SA - Belgium

Former Professional at UCB S. A.

Former Senior Partner at McKinsey & Co., Inc. (Belgium)

Former President & Chief Executive Officer at H. Lundbeck A/S

Former Chief Executive Officer & Chairman of the Executive Committee at UCB S. A.

Chief Executive Officer & Director at IDS Capital (UK) Ltd.

Professional at OxStem Ltd.

Member-Strategic Board at NeoMedLight SAS

Director-Health Research Strategy at World Health Organization /Europe

Head at Nikita SPRL

Paths to UCB S. A.
Potential Connections via
Relationship Science
Owners & Shareholders
Details Hidden

Wellington is an active manager which invests across a range of equity, fixed-income, commodities, alternative and other investment classes following a variety of strategies. Portfolio managers are responsible for both research and investment decisions within their territory, supported by proprietary research which is shared throughout the Wellington group. Their focus is primarily on the UK, Europe, the Middle East and Africa.The firm's proprietary research is the foundation for their investment approach, and is used by specialized teams to invest according to their specific strategies, which combine fundamental research with quantitative valuation techniques. Risk management combines proprietary models and external systems to ensure that portfolios are constructed in line with client risk tolerance.Global industry, regional and macroeconomic experts support both equity and fixed-income investments. Quantitative, technical, style and specialty research teams also contribute to the equity investment processes. Credit, sovereign, quantitative and sector-based analysts support fixed-income investing, working as teams to ensure that bottom-up decisions include relevant top-down factors, and vice versa.Wellington's multi-sector portfolios are regional and multi-currency. They cover the duration spectrum from money market and short bond to intermediate and market duration, core, and core bond plus portfolios. The firm also invests in specific sectors including high yield, corporate, mortgage-backed, emerging markets, and municipal bonds.

Details Hidden

Zadig Asset Management LLP (ZAM) is an independent hedge fund company based in London, UK. The firm was established in 2005 by Laurent Saglio to manage the Zadig Fund, a hedge fund for private individuals and institutions now closed to new investors.Before founding ZAM, Laurent Saglio participated in the creation of Voltaire Asset Management in 1998, which was closed in 2005 after the retirement of Ivan Briery, the firm's other founding partner.

Details Hidden

Hermes Equities is an active, long-term manager which specializes in high-alpha, unconstrained European equity portfolios. They aim to build portfolios of high-conviction, original ideas that will outperform the benchmark without excessive volatility.The firm selects stocks based on a bottom-up approach where they can identify sustained structural change in businesses yet to be recognized by the market. They conduct in-house research, focusing on the key drivers of a business model including capital and product cycles, cash flow, relative value, buyer and supplier power, barriers to entry and secular growth trends.Hermes Equities tests investment ideas against a macroeconomic and thematic framework, seeking emerging fundamental themes that can lead to structural bottlenecks and which could spark a re-pricing of the stocks operating in these areas.

Recent Transactions
Details Hidden

UCB S. A. purchases Element Genomics, Inc.

Details Hidden

UCB S. A. purchases Beryllium Discovery Corp.

Details Hidden

Amphastar Pharmaceuticals, Inc., Amphastar (United Kingdom) Ltd. purchase International Medication Systems (United kingdom) Ltd. from UCB S. A.

Transaction Advisors

Advised onUCB S. A. purchases Solutia, Inc. /Resins Additives & Adhesives Businesses from Solutia, Inc.

Investment Advisor

Advised onUCB S. A. purchases UCB Pharma GmbH

Legal Advisor

Advised onUCB S. A. purchases Beryllium Discovery Corp.


Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Legal Advisor

Advised onCytec Industries, Inc. purchases UCB SA /Surface Specialty Business from UCB S. A.

Legal Advisor

Advised onLannett Co., Inc. purchases Kremers Urban Pharmaceuticals, Inc. from UCB S. A.

Advisors & Consultants
Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP


McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Stats and Financials As of 2017
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Debt
Total Equity
Enterprise Value Sales
Enterprise Value EBITDAOperating
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Five Year Compounded Annual Growth Rate Of Revenue
Details Hidden

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Details Hidden

Lumos Pharma, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Details Hidden

Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada.

Evotec AG Pharmaceuticals | Hamburg, HA

Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

BTS Group AB Management Consulting | Stockholm, AB

BTS Group AB engages in the provision of consultancy solutions and training services. It operates through the following segments: North America, Europe, Other Markets, and APG. The North America segment consists of the company's operations in North America excluding APG. The Europe segment includes Belgium, Finland, France, Germany, the Netherlands, Sweden, and the UK. The Other Markets segment handles operations in Argentina, Australia, Brazil, China, Costa Rica, Dubai, India, Italy, Japan, Mexico, Singapore, South Africa, South Korea, Spain, Taiwan, and Thailand. The APG segment covers the operations of Advantage Performance Group in North America. The company was founded by Henrik Ekelund in 1986 and is headquartered in Stockholm, Sweden.

Nektar Therapeutics Pharmaceuticals | San Francisco, CA

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.